Patent · US Active

Antibodies against Tenascin-C

US7968685B2 · kind B2 · utility

9Cited by

0References

14Claims

0Family size

Assignee

PHILOGEN S.P.A. · IT

Inventors

Simon Brack · Winterthur, CH
Michela Silacci · Zürich, CH
Dario Neri · Zürich, CH

Key dates

Filing date	Oct 31, 2005
Grant date	Jun 28, 2011
Priority date	—
Expiry date	Mar 2, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/565
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.